Earnings call transcript: Akums Drugs posts strong Q2 FY 2027 revenue beat

Akums Drugs and Pharmaceuticals reported a sharp increase in revenue and a more than doubling of profit in Q2 FY 2027. The company's revenue grew to INR 1,342 crores, surpassing forecasts by around 26.8%, while EBITDA more than doubled to INR 195 crores. The company's contract development and manufacturing operations (CDMO) continued to drive growth, accounting for 83% of quarterly revenue.

The company's strong performance was attributed to robust demand across existing and new customers, improved utilization of newer facilities, and a solid order book. Akums also highlighted its expanding product pipeline and growing presence in regulated markets. The stock rallied 1.44% to $743.7 following the earnings release, trading near the top of its 52-week range.